We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The mounting safety concerns swirling around the pharmaceutical industry are
beginning to have a profound effect on the American public's perception of drug
companies, according to a recent online poll.
GTC Biotherapeutics will sell $10.4 million in common stock in an effort to
raise money to fund clinical trials and product development, the company announced.
Nitin Sahney, president of RxCrossroads has announced the launch of an industry-leading
manufacturer focused mail-order pharmacy automation platform. RxCrossroads is
a leader in providing product support services to pharmaceutical, biotech and
medical device companies.
GlaxoSmithKline said plans to eliminate 250 positions -- roughly half of
which will be in the Philadelphia region -- in its U.S Pharmaceuticals division
in February.
Bayer HealthCare AG and Nektar Therapeutics have announced a new collaboration
to develop an inhaleable powder formulation of a novel form of Ciprofloxacin
(Cipro) to treat chronic lung infections caused by Pseudomonas aeruginosa (P.
aeruginosa) in cystic fibrosis patients.
Germany's generic drugmaker Stada Arzneimittel AG
has completed the previously announced acquisition of one of Russia's top three
pharmaceutical companies, Nizhpharm.
Wyeth has initiated settlement discussions with an undisclosed number of plaintiffs
who opted out of the National Diet Drug Settlement, which was inked in 1999
to address claims filed over Wyeth's diet drugs Pondium and Redux, the company
said.